Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6-11 Years of Age with Severe Atopic Dermatitis.
Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Chen Z, Thomas RB, Kosloski MP, Dubost-Brama A, Prescilla R, Bansal A, Levit NA. Cork MJ, et al. Among authors: thomas rb. Dermatol Ther (Heidelb). 2023 Nov;13(11):2697-2719. doi: 10.1007/s13555-023-01016-9. Epub 2023 Sep 26. Dermatol Ther (Heidelb). 2023. PMID: 37750994 Free PMC article.
Estimating meaningful change thresholds for Skin Pain-Numeric Rating Scale, Sleep-Numeric Rating Scale and Dermatology Life Quality Index in patients with prurigo nodularis.
Stander S, Kim BS, Guillemin I, Rhoten S, Wratten S, Brookes E, O'Malley JT, Bansal A, Msihid J, Thomas R, Bahloul D. Stander S, et al. J Eur Acad Dermatol Venereol. 2024 Jul;38(7):1401-1409. doi: 10.1111/jdv.19800. Epub 2024 Feb 8. J Eur Acad Dermatol Venereol. 2024. PMID: 38329222
Responder analysis using clinically meaningful thresholds: Post hoc analyses from randomized dupilumab clinical trials in patients with prurigo nodularis.
Kwatra SG, Yosipovitch G, Ständer S, Guillemin I, Msihid J, Bansal A, Makhija M, Wiggins S, Zahn J, Thomas RB, Bahloul D. Kwatra SG, et al. Among authors: thomas rb. J Eur Acad Dermatol Venereol. 2024 Oct;38(10):1965-1972. doi: 10.1111/jdv.20099. Epub 2024 May 24. J Eur Acad Dermatol Venereol. 2024. PMID: 38785405 Clinical Trial.
Burden of Disease of Bullous Pemphigoid: A Targeted Literature Review.
Bahloul D, Dubucq H, Thomas RB, Ajith A, Boss J, Fotheringham I, Kumichel A. Bahloul D, et al. Among authors: thomas rb. Dermatology. 2024;240(5-6):823-832. doi: 10.1159/000540480. Epub 2024 Aug 27. Dermatology. 2024. PMID: 39191228 Free article. Review.
Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials.
Silverberg JI, Lynde CW, Abuabara K, Patruno C, de Benedetto A, Zhang H, Thomas RB, Bégo-Le-Bagousse G, Khokhar FA, Vakil J, Marco AR, Levit NA. Silverberg JI, et al. Among authors: thomas rb. Am J Clin Dermatol. 2023 May;24(3):469-483. doi: 10.1007/s40257-022-00754-4. Epub 2023 Feb 20. Am J Clin Dermatol. 2023. PMID: 36808602 Free PMC article.
Dupilumab Provides Clinically Meaningful Responses in Children Aged 6-11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase III Trial.
Siegfried EC, Cork MJ, Katoh N, Zhang H, Chuang CC, Thomas RB, Rossi AB, Cyr SL, Zhang A. Siegfried EC, et al. Among authors: thomas rb. Am J Clin Dermatol. 2023 Sep;24(5):787-798. doi: 10.1007/s40257-023-00791-7. Epub 2023 Jun 10. Am J Clin Dermatol. 2023. PMID: 37300760 Free PMC article. Clinical Trial.
Similarities and Differences in the Perception of Atopic Dermatitis Burden Between Patients, Caregivers, and Independent Physicians (AD-GAP Survey).
Paller AS, Weidinger S, Capozza K, Pink AE, Tang M, Guillaume X, Praestgaard A, Leclerc M, Chuang CC, Thomas RB, Prescilla R. Paller AS, et al. Among authors: thomas rb. Dermatol Ther (Heidelb). 2023 Apr;13(4):961-980. doi: 10.1007/s13555-022-00850-7. Epub 2023 Mar 15. Dermatol Ther (Heidelb). 2023. PMID: 36922463 Free PMC article.
Publisher Correction to: Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials.
Silverberg JI, Lynde CW, Abuabara K, Patruno C, de Benedetto A, Zhang H, Thomas RB, Bégo-Le-Bagousse G, Khokhar FA, Vakil J, Marco AR, Levit NA. Silverberg JI, et al. Among authors: thomas rb. Am J Clin Dermatol. 2023 Jul;24(4):673. doi: 10.1007/s40257-023-00784-6. Epub 2023 May 17. Am J Clin Dermatol. 2023. PMID: 37193879 Free PMC article. No abstract available.
112 results